PSNL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Personalis Inc (PSNL) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown some positive developments in its cancer monitoring technology and slight improvements in financial performance, the technical indicators, options sentiment, and lack of strong trading signals suggest a cautious approach. The stock's bearish moving averages, low RSI, and weak near-term price trend make it less attractive for immediate entry.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 27.567, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Support levels are at 5.854, with resistance at 6.37. The stock has a 70% chance to decline -0.69% in the next day and -6.54% in the next month.
Personalis presented promising data at the AACR Annual Meeting, showcasing the effectiveness of its NeXT Personal technology in cancer treatment monitoring. The launch of the Real-Time Variant Tracker™ adds innovation to its product line.
Bearish technical indicators and weak near-term price trend. Analysts have lowered price targets, and the stock has a high probability of declining in the short term. Gross margin dropped significantly (-59.56% YoY), indicating cost pressures.
In Q4 2025, revenue increased by 3.24% YoY to $17.35M, and net income improved by 44.97% YoY but remains negative at -$23.81M. EPS improved to -0.26, up 13.04% YoY. However, gross margin dropped significantly to 10.95%, down -59.56% YoY.
Analysts are mixed. Morgan Stanley lowered its price target to $10 from $11, maintaining an Equal Weight rating. Guggenheim raised its price target to $13 from $12, maintaining a Buy rating. The updates reflect higher operating expenses and mixed sentiment on the company's financial outlook.
